|Bid||0.00 x 3200|
|Ask||0.00 x 800|
|Day's Range||44.54 - 45.98|
|52 Week Range||44.30 - 63.69|
|Beta (3Y Monthly)||0.79|
|PE Ratio (TTM)||14.31|
|Forward Dividend & Yield||1.64 (3.58%)|
|1y Target Est||N/A|
Bristol-Myers Squibb Company (BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (CELG). The Company remains actively engaged in discussions with the U.S. Federal Trade Commission (“FTC”) on the FTC’s continued review of the proposed transaction. To allow the transaction to close on a timely basis in light of concerns expressed by the FTC, the Company is planning the divestiture of OTEZLA® (apremilast).
Bristol-Myers Squibb Company today announced topline results from CheckMate -459, a randomized Phase 3 study evaluating Opdivo versus sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma .
Bristol-Myers Squibb Company (BMY) and Catalent, Inc. (CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.
In a descriptive analysis, addition of Empliciti to pomalidomide and dexamethasone reduced risk of death by 46% among patients with RRMM
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.
Bristol-Myers Squibb Company (BMY) today announced data from a Phase IV mechanistic study exploring differences in the cellular and molecular mechanisms by which ORENCIA® (abatacept) and another treatment, adalimumab, interfere with disease progression in moderate-to-severe early rheumatoid arthritis (RA) patients seropositive for certain autoantibodies. Among 80 adult patients with early (≤ 12 months from symptom onset) moderate-to-severe RA who had never been treated with a biologic medication and tested positive for autoantibodies called anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF), numerically higher efficacy responses were seen with ORENCIA at week 24. ACR 20/50/70 scores for adalimumab were 63, 45 and 30, respectively.
Bristol-Myers Squibb Company will announce results for the second quarter of 2019 on Thursday, July 25, 2019. During a conference call at 10:30 a.m. ET on July 25, company executives will review financial information and will address inquiries from investors and analysts.
Bristol-Myers Squibb Company (BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with Celgene Corporation (CELG). The company is evolving key aspects of its R&D and Commercialization structure to drive the continued growth of a highly successful marketed portfolio, maximize the six near-term launch opportunities and deliver the value of the combined pipeline, all guided by its continued mission of serving patients with serious disease.
Bristol-Myers Squibb Company will take part in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019, in Rancho Palos Verdes, CA. Chris Boerner, Executive Vice President, Chief Commercial Officer, will answer questions about the company at 11:00 a.m.
Five-year follow-up analysis from Phase 1 CA209-004 study provides evidence of long-term survival following discontinuation of treatment in patients with advanced melanoma
Opdivo plus Yervoy yielded objective response rate of 31% and median duration of response of 17.5 months
Bristol-Myers Squibb Company announced today the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the ...
New data on Opdivo plus Yervoy in patients with advanced hepatocellular carcinoma and in melanoma patients with symptomatic brain metastases
PRESS RELEASE : 16 May 2019, 07:00 CEST Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference Mechelen, Belgium, 16 May 2019 - Biocartis Group NV (the `Company` or `Biocartis`), ...
Two-time Emmy Award winner Sterling K. Brown (This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life after a cancer diagnosis. Survivorship Today: What It’s Like to Live with Cancer explores the stories of people who have experienced lasting physical, emotional and social effects from cancer to build greater understanding of, and draw attention to, survivorship-related issues. Today, more people who have been diagnosed with cancer are able to live with the disease than ever before.
Bristol-Myers Squibb Company will take part in a fireside chat at the UBS Global Healthcare Conference on Tuesday, May 21, 2019, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 2:30 p.m.
Bristol-Myers Squibb Company today announced the Phase 3 CheckMate -498 trial evaluating Opdivo plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase -unmethylated glioblastoma multiforme did not meet its primary endpoint of overall survival at final analysis.
Bristol-Myers Squibb Company (BMY) (“Bristol-Myers Squibb”) today announced that it priced its previously announced private offering (the “Offering”) of senior unsecured notes in a combined aggregate principal amount of $19 billion (collectively, the “Notes”). Bristol-Myers Squibb expects that the closing of the Offering will occur on May 16, 2019, subject to the satisfaction of customary closing conditions.
Bristol-Myers Squibb Company announced today that the requisite number of consents have been received to adopt proposed amendments with respect to all outstanding notes of Celgene Corporation .
Bristol-Myers Squibb Company (BMY) (“Bristol-Myers Squibb”) today announced that, subject to market and other conditions, it intends to commence a private offering (the “Offering”) to sell senior unsecured notes (the “Notes”). The Offering is being conducted in connection with the previously announced proposed acquisition (the “Merger”) of Celgene Corporation (“Celgene”). Bristol-Myers Squibb expects to use the net proceeds from the Offering to fund a portion of the aggregate cash portion of the merger consideration to be paid to Celgene shareholders in connection with the Merger and to pay related fees and expenses, with any remaining proceeds being used for general corporate purposes.
NEW YORK-- -- Increases First Quarter Revenues 14% to $5.9 Billion Posts First Quarter GAAP EPS of $1.04 and Non-GAAP EPS of $1.10 Announces Shareholder Approval of Celgene Acquisition Presents Important New Data at American Association for Cancer Research and American College of Cardiology Annual Meetings Reaffirms Non-GAAP EPS Guidance Range of $4.10-$4.20 and Increases GAAP EPS Guidance Range to ...
PRESS RELEASE : REGULATED INFORMATION Thursday 25 April 2019, 07:00 CEST BIOCARTIS Q1 2019 BUSINESS UPDATE Mechelen, Belgium , 25 April 2019 - Biocartis Group NV (the `Company` or `Biocartis`), an innovative ...
Bristol-Myers Squibb Company announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation , of an exchange offer for any and all outstanding notes issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb and cash.
Bristol-Myers Squibb Company (BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (CELG) at the Special Meeting of Stockholders. “We are pleased with the outcome of today’s Special Meeting and thank our shareholders for their support for this combination,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines.